Metabolomics diagnostic approach to mustard airway diseases: a preliminary study
- Iran J Basic Med Sci. 2018 Jan;21(1):59-69. doi: 10.22038/IJBMS.2017.23792.5982.
- 1. Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.
- 2. Pulmonary Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- 3. Department of Basic Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 4. Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 5. Chronic Kidney Disease Research Center, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 6. Department of Chemistry, Faculty of Sciences, Tarbiat Modares University, Tehran, Iran.
- 7. Physiotherapy Research Center, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 8. Department of Chemistry, Sharif University of Technology, Tehran, Iran.
- 9. Department of Chemistry, Faculty of Science, University of Tehran, Tehran, Iran.
Objectives: This study aims to evaluate combined proton nuclear magnetic resonance (1H NMR) spectroscopy and gas chromatography-mass spectrometry (GC-MS) metabolic profiling approaches, for discriminating between mustard airway diseases (MADs) and healthy controls and for providing biochemical information on this disease.
Materials and methods: In the present study, analysis of serum samples collected from 17 MAD subjects and 12 healthy controls was performed using NMR. Of these subjects, 14 (8 patients and 6 controls) were analyzed by GC-MS. Then, their spectral profiles were subjected to principal component analysis (PCA) and orthogonal partial least squares regression discriminant analysis (OPLS-DA).
Results: A panel of twenty eight metabolite biomarkers was generated for MADs, sixteen NMR-derived metabolites (3-methyl-2-oxovaleric acid, 3-hydroxyisobutyrate, lactic acid, lysine, glutamic acid, proline, hydroxyproline, dimethylamine, creatine, citrulline, choline, acetic acid, acetoacetate, Cholesterol, alanine, and lipid (mainly VLDL)) and twelve GC-MS-derived metabolites (threonine, phenylalanine, citric acid, myristic acid, pentadecanoic acid, tyrosine, arachidonic acid, lactic acid, propionic acid, 3-hydroxybutyric acid, linoleic acid, and oleic acid). This composite biomarker panel could effectively discriminate MAD subjects from healthy controls, achieving an area under receiver operating characteristic curve (AUC) values of 1 and 0.79 for NMR and GC-MS, respectively.
Conclusion: In the present study, a robust panel of twenty-eight biomarkers for detecting MADs was established. This panel is involved in three metabolic pathways including aminoacyl-tRNA biosynthesis, arginine, and proline metabolism, and synthesis and degradation of ketone bodies, and could differentiate MAD subjects from healthy controls with a higher accuracy.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Endogenous MetaboliteResearch Areas: Metabolic Disease
-
target: Endogenous MetaboliteResearch Areas: Metabolic Disease
-
Research Areas: Metabolic Disease
-
Research Areas: Metabolic Disease